Leprosy therapy, past and present: Can we hope to eliminate it?

Indian Journal of Dermatology

Volumn 55, Issue 4, 2010, Pages 316-324

  Prasad, P V S ^a   Kaviarasan, P K ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

drugs in leprosy; Elimination of leprosy; leprosy therapy; multidrug therapy

Indexed keywords

ACETYLSALICYLIC ACID; CHLOROQUINE; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DNA; LEPROSTATIC AGENT; LEVAMISOLE; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PENTOXIFYLLINE; PHOSPHODIESTERASE IV INHIBITOR; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; STEROID; THALIDOMIDE; THALIDOMIDE DERIVATIVE; ZINC;

ADD ON THERAPY; ARTICLE; BACTERIAL TRANSMISSION; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; DNA SEQUENCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; GENOME; HUMAN; IMMUNOTHERAPY; INFECTION RESISTANCE; LEPROSY; LEPROSY CONTROL; MEDICAL TECHNOLOGY; MULTICENTER STUDY (TOPIC); MYCOBACTERIUM LEPRAE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE DRUG DOSE; TERATOGENICITY; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

EID: 78651309126     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.74528     Document Type: Article

References (68)

1. WHO study group. Chemotherapy of leprosy for control programs. Report of WHO study. World Health Organ Tech Rep Ser 1982;675
2. WHO Global leprosy situation. Wkly Epidemiol Rec. WHO 15th August 2008.
3. Report of the International Leprosy Association Technical Forum. Lepr Rev 2002;73:513-6.
4. Lockwood DN. Steroids in leprosy type-1 reactions: Mechanism of actions and effectiveness. Lepr Rev 2000;71:111-4.
5. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser 1988;768:1-51.
6. Report of the third meeting of the WHO technical advisory group on the elimination of leprosy. WHO/CDS/CPE/CEE/2002/29. Geneva, WHO.
7. Pardillo FE, Fajarado TT, Abalos RM. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis 2007;44:1096-9.
8. Lockwood DN, Sarno E, Smith WC. Classifying leprosy patients - searching for the perfect solution? Lepr Rev 2007;78:317-20.
9. Noordeen SK. Epidemiology of poly neuritic type of leprosy. Lepr India 1972;44:85-93.
10. Operational guidelines on case detection, treatment, followup and reporting forms NLEP. Leprosy division. Directorate General of Health Services. New Delhi, 1992.
11. WHO Expert Committee on Lprosy. World Health Organ Tech Rep Ser 1998;874:1-43.
12. Efficacy of single dose multi drug therapy for treatment of single lesion paucibacillary leprosy. Single lesion multi centered trial group. Indian J Lepr 1997;69:121-9.
13. Final push strategy to elimination of leprosy as a public health problem. Questions and Answers. WHO document. 2nd ed. Geneva; WHO: 2003.
14. Shepard CC. A brief review of experience with short-term clinical trials monitored by mouse foot pad inoculation. Lepr Rev 1981;52:299-308.
15. Venkatesan K. Pharmacokinetics and drug interactions of newer anti-leprosy drugs. Indian J Dermatol Venereol Leprol 1997;63:148-52.
16. Katoch K. New emerging drug regimens for leprosy. Indian J Dermatol Venereol Leprol 1997;63:130-47.
17. Jacobson RR. Needed research in chemotherapy of leprosy related to the individual patient. Int J Lepr Other Mycobact Dis 1996;64:S16-20.
18. Ji B. Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother 1998;42:1115-20.
19. Daumerie D. Current World Health Organization-sponsored studies in the chemotherapy of leprosy. Lepr Rev 2000;71:88-90.
20. Ji B, Truffort-Pernot C, Lacriox C, Raviglione MC, OBrien RJ, Olliaro P, et al. Effectiveness of rifampicin, rifabutin and rifapentine for preventive therapy for tuberculosis in mice. Am Rev Respir Dis 1993;148:1541-6.
21. Consigny S. Bactericidal activities of HMR 3647, moxifloxicin and rifapentines against Mycobacterium leprae in mice. Antimicrob Agents Chemother 2000;44:2919-21.
22. Grosset JH. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis 1989;57:607-14.
23. World Health Organisation. Report of the ninth meeting of the WHO technical advisory group on leprosy control: Cairo, Egypt, 6-7 March 2008. Lepr Rev 2008;79:452-70.
24. Katoch K. Chemotherapy trials in MB leprosy using conventional and newer drugs Ofloxacin and minocycline. Indian J Dermatol Venereol Leprol 2000;66:18-25.
25. Ganapati R, Pai VV, Shroff HJ, Gandewar K. Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions. Int J Lepr Other Mycobact Dis 1997;65:264-6.
26. Report on the Third Meeting of the WHO Technical Advisory Group on Elimination of Leprosy. Geneva, World Health Organization, 2002 (document number WHO/CDS/CPE/CEE/2002.29).
27. Prasad PV, Babu A, Kaviarasan PK, Viswanathan P, Tipoo R. MDT-MB therapy in paucibacillary leprosy: A clinic pathological assessment. Indian J Dermatol Venereol Leprol 2005;71:242-6.
28. Ellard GA. Drug compliance in the treatment of leprosy. Lepr Rev 1981;52:201-13.
29. Ellard GA. Clofazimine and dapsone compliance in leprosy. Lepr Rev 1988;59:205-13.
30. Guide to eliminate leprosy as a public health problem. 1st ed. Geneva: World Health Organization; 2000
31. Ji B. Chemotherapy and chemoprophylaxis of leprosy. Report of Scientific Working Group on leprosy TDR/SWG 2002.
32. Honoré N, Cole ST. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 1993;37:414-8.
33. Cambau E. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 2002;34:39-45.
34. Matsuoka M, Kashiwabara Y, Namisato M. A Mycobacterium leprae isolate resistant to dapsone, rifampin and sparfloxacin. Int J Lepr Other Mycobact Dis 2000;68:452-5.
35. Maeda S. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother 2001;45:3635-9.
36. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED, et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed patients from Myanmar, Indonesia and the Philippines. Lepr Rev 2007;78:343-52.
37. Nguyr LN, Cartel JL, Grosset JH. Chemoprophylaxis of leprosy in the Southern Marquises with a single 25 mg/kg dose of rifampicin. Results after 10 years. Lepr Rev 2000;71:S33-6.
38. Marlowe SN, Leekassa R, Bizuneh E, Knuutilla J, Ale P, Bhattarai B, et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg 2007;101:1004-12.
39. Walker SL, waters MF, Lockwood DN. The role of thalidomide in the management erythema nodosum leprosum. Lepr Rev 2007;78:197-215.
40. Kaplan G. Potential of thalidomide and thalidomide analogues as immuno modulatory drugs in leprosy and leprosy reactions. Lepr Rev 2000;71:S117-20.
41. Sales AM, de Matos HJ, Nery JA, Duppre NC, Sampaio EP, Sarno EN. Double blind trial of the efficacy of pentoxifylline vs. thalidomide for the treatment of type-II reaction in leprosy. Braz J Med Biol Res 2007;40:243-8.
42. Girdhar BK, Girdhar A, Chakma JK. Advances in the treatment of reactions in leprosy. Indian J Lepr 2007;79:121-34.
43. Feuth M, Wim Brandsma J, Faber WR, Bhattarai B, Feuth T, Anderson AM. Erythema nodosum leprosum in Nepal: A retrospective study of clinical features and response to treatment with prednisolone or thalidomide. Lepr Rev 2008;79:254-69.
44. Hastings RC, Job CK. Reversal reactions in lepromatous leprosy following transfer factor therapy. Am J Trop Med Hyg 1978;27:995-1004.
45. Mathur NK. Long term follow up of lepromatous leprosy patients receiving intra lesional recombinant gamma interferon. Int J Lepr Other Mycobact Dis 1992;60:98-100.
46. Kaplan G. The systemic influence of recombinant interlekin-2 on the manifestations of lepromatous leprosy patients. J Exp Med 1991;173:993-1006.
47. Gillis T. Is there a role for vaccine in leprosy control? Lepr Rev 2007;78:338-42.
48. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998;76:S22-5.
49. Richardus JH, Habbema JD. The impact of leprosy control on the transmission of M. leprae: Is elimination being attained? Lepr Rev 2007;78:330-7.
50. Meima A, Gupte MD, van Oortmarssen GJ, Habbema JD. Trends in leprosy case detection rates. Int J Lepr Other Mycobac Dis 1997;65:305-19.
51. Fine PE, Warndorff DK. Leprosy by the year 2000- what is being eliminated? Lepr Rev 1997;68:201-2.
52. Smith WC. We need to know what is happening to the incidence of leprosy. Lepr Rev 1997;68:195-200.
53. Report of the International Leprosy Association Technical Foum. 25-28 February 2002. Paris, France. Lepr Rev 2002;73:S3-61.
54. Meima A, Richardus JH, Habbema JD. Trends in leprosy case detection worldwide since 1985. Lepr Rev 2004;75:19-33.
55. Global leprosy situation, 2007. Wkly Epidemiol Rec 2007;82:225-32.
56. Fine PE, Smith PG. Vaccination against leprosy - the view from 1996. Lepr Rev 1996;67:249-52.
57. International Leprosy Association Technical Forum. Report. Lepr Rev 2002;73:S1-62.
58. Fine PE. Leprosy: The epidemiology of slow bacterium. Epidemiol Rev 1982;4:161-88.
59. Meima A. The impact of multi drug therapy on trends in transmission of leprosy. Report of the Scientific Working Group on Leprosy 2002. TDR/SWG/02.
60. van Beers SM, Hatta M, Klatser PR. Patient contact is the major determinant in incident leprosy: Implications for future control. Int J Lepr Other Mycobact Dis 1999;67:119-28.
61. Deps PD, Alves BL, Gripp CG, Aragao RL, Guedes BV, Filho JB, et al. Contact with armadillos increases the risk of leprosy in Brazil: A case control study. Indian J Dermatol Venereol Leprol 2008;74:338-42.
62. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 2008;83:293-300. Available from: http://www.who.int/wer[last cited on 2008 Dec 15].
63. Fine PE. Leprosys global statistics- still room for improvement. Lepr Rev 2008;79:235-8.
64. Rao PN, Lakshmi TS. Final push of leprosy in India: What is being pushed? Indian J Dermatol Venereol Leprol 2005;71:226-9.
65. World Health Organization Regional Office for South-East Asia New Delhi. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010 Operational Guidelines. Lepr Rev 2006:77:1-50.
66. Richardus JH, Habbema JD. The impact of leprosy control on the transmission of M. leprae; is elimination being attained? Lepr Rev 2007;78:330-7.
67. Scollard DM. Leprosy research declines, but most of the basic questions remain unanswered. Int J Lepr Other Mycobact Dis 2005;73:25-7.
68. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbio Rev 2006;19:338-81.